ARTICLE | Clinical News
BNP7787 water soluble disulfide chemoprotectant regulatory update
March 13, 2000 8:00 AM UTC
The FDA granted fast track designation for BNP7787 to prevent or decrease nerve damage associated with paclitaxel treatment for cancer. The compound is in Phase I trials. ...